• Publications
  • Influence
Neurotensin expression and outcome of malignant pleural mesothelioma.
Malignant pleural mesothelioma is a frequently fatal disease and the impact of available treatments is globally poor. Identification of new prognostic factors would help in the understanding ofExpand
  • 21
  • 2
Prognostic significance of vascular and lymphatic emboli in resected pulmonary adenocarcinoma.
BACKGROUND The incidence of vascular and lymphatic emboli in a specimen of resected non-small cell lung cancer is variable according to different authors' experience as well as prognosticExpand
  • 16
  • 2
Sexual Function in Patients Treated With Stereotactic Radiotherapy For Prostate Cancer: A Systematic Review of the Current Evidence.
INTRODUCTION Sexual function can be impaired by all prostate cancer treatment modalities, but studies specifically addressing the impact of stereotactic body radiotherapy (SBRT) on sexual functionExpand
  • 3
  • 1
Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management.
BACKGROUND Oligometastatic stage IV non-small lung cancer (NSCLC) patients have a 5-year overall survival of 30% versus 4% to 6% in historical cohorts of stage IV NSCLC patients. We reviewed data andExpand
  • 10
  • 1
Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis
Background: Stereotactic ablative body radiation therapy (SBRT) has evolved as the standard treatment for patients with inoperable stage I non–small‐cell lung cancer (NSCLC). We report the results ofExpand
  • 7
Neoadjuvant treatment of soft tissue sarcoma
PurposeThe aim of this study was to evaluate disease-free survival (DFS), overall survival and toxicity of patients who underwent preoperative therapy for soft tissue sarcoma.Materials and methodsTheExpand
  • 9
Single-Fraction Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Relapse in Prostate Cancer
Background: Stereotactic body radiotherapy (SBRT) emerged as a treatment option in oligometastatic (≤3 metastases) patients experiencing lymph node relapse from treated prostate cancer. NoExpand
  • 3
Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.
AIM This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17Expand
  • 1
Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: A randomized, placebo controlled, phase III trial—SAFE trial.
TPS1100 Background: Anthracyclines and trastuzumab play a key-role in preoperative and adjuvant breast cancer (BC) treatment, and showed a significant survival benefit in several trials. AlthoughExpand
  • 1
Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer.
INTRODUCTION Adrenal gland metastases occur in up to 20% of patients with non-small-lung cancer. In selected cases with limited burden of disease, surgery may be offered to improve patient outcome;Expand
  • 2